Monte Rosa Therapeutics, Inc. (GLUE): Total Assets
$448.66M
As of 2025-12-31
$691.16M
As of 2026-06-30
+9.4%
3-year compound annual growth
+55.5%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $448.66M | +2.3% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $438.73M | +44.4% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $303.75M | -11.3% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $342.39M | -6.5% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $366.33M | +641.9% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $49.38M | n/a | 2022-03-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $448.66M | +2.3% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $20.23M | -81.5% |
| Agenus Inc (AGEN) | 2025-12-31 | $226.80M | +0.2% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $501.90M | +31.1% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $1.48B | +34.2% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $223.70M | -36.7% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $173.83M | -55.1% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $1.12B | -18.7% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $453.03M | -2.8% |
Compare GLUE, ATRA, AGEN, IBRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗